News (204)

Alnylam Issues 2023 Corporate Responsibility Report BU
Alnylam Pharmaceuticals : 2023 REPORT PU
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity BU
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen's Association AQ
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:45 AM
Alnylam Announces Preliminary Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates AQ
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 09:30 AM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-14-2023 10:00 AM
Transcript : Alnylam Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis BU
Transcript : Alnylam Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Roche to co-develop hypertension RNAi therapeutic AQ
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk GL
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk BU
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 04, 2023
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity BU
Alnylam Issues 2022 Corporate Responsibility Report BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy BU
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy GL
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy AQ
PACIRA BIOSCIENCES, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K) AQ
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors GL
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors AQ
Pacira Biosciences Announces Yvonne Greenstreet to Retire from Board of Directors CI
Alnylam Announces Appointment of Peter Kellogg to Board of Directors BU
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2022 Earnings Call, Feb 23, 2023
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:45 AM
Alnylam Announces Preliminary Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates AQ
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates BU
Alnylam Announces Updates to its Board of Directors BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Ranks 1 on Boston Globe's Top Places to Work List for 2022 AQ
1234NextSee all

Insiders

Picture Yvonne Greenstreet
Yvonne Greenstreet

Yvonne L. Greenstreet founded Highgate LLC. Currently, Dr. Greenstreet is President & Chief Operating Officer of Alnylam Pharmaceuticals, Inc. Dr. Greenstreet is also on the board of Pacira Biosciences, Inc. and Member of The Association of the British Pharmaceutical Industry. Dr. Greenstreet previously occupied the position of Managing Director at Highgate LLC, Senior Vice President & Head-Medicines Development at Pfizer Inc. and Chief Strategy-R&D, Senior Vice President at GlaxoSmithKline Plc. Yvonne L. Greenstreet received an MBA from INSEAD and an undergraduate degree from the University of Leeds.


Picture Michelle M. Greenstreet
Michelle M. Greenstreet

Michelle M.
Greenstreet
formerly worked at Citibank NA (New York), as Senior Vice President & Director-Human Resource, United Parcel Service, Inc., as Principal, Texas Workforce Commission, as Principal, Caliber Home Loans, Inc., as Chief Human Resources Officer & Executive VP from 2012 to 2014, Vericrest Financial, Inc., as Chief Human Resources Officer, and Spirit Realty Capital, Inc., as Chief Administrative Officer & Executive VP.
Ms. Greenstreet received her undergraduate degree from Texas A&M University.








Picture Ian Greenstreet
Ian Greenstreet

Ian O.
Greenstreet
is the founder of Infinity Capital Partners Ltd.
He currently holds positions as an Independent Non-Executive Director at The Principality Building Society and at Simmons & Simmons LLP.
Previously, he held positions as an Independent Non-Executive Director at Lesaka Technologies, Inc., an Independent Director at Diamond Bank Plc, and as a Director & Head at Henderson Fund Management (Luxembourg) SA, among others.
He received his undergraduate degree from The University of Manchester.


No results for this search

  1. Stock Market
  2. Advanced search
  3. Yvonne Greenstreet
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW